Cash flow Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:39:16 2025-02-13 pm EST			5-day change	1st Jan Change
14.02 ^USD	+0.75%		-15.60%	-39.96%

Jan. 21	Dyne Therapeutics Says US FDA Grants Fast Track tag to Neuromuscular Disease Therapy	MT
Jan. 21	Dyne Gets FDA Fast-Track Status for Neuromuscular Product Candidate	DJ

dad0a03423df75882bbc3184fd8.2o-2zeOSDkBMlbXvHytG6QW_p4oFC3Fbr3_THvGFvxc.o_XBqbfzZBg__eWwZVExmHKO4b1AWEYZmQmFR6PJ7li7__qgm-J9GDS45A

Published financial data: DYNE THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Selling General & Admin Expenses, Total	2.79M	13.45M	28.72M	28.2M	31.4M
R&D Expenses	11.04M	45.2M	121M	143M	211M
Other Operating Expenses, Total	13.83M	58.65M	150M	171M	242M
Operating Income	-13.83M	-58.65M	-150M	-171M	-242M
Interest Expense, Total	-	-396K	-	-	-
Interest And Investment Income	290K	56K	742K	2.92M	7.64M
Net Interest Expenses	290K	-340K	742K	2.92M	7.64M
Currency Exchange Gains (Loss)	-	-	-	-20K	-1.39M
Other Non Operating Income (Expenses)	-	-450K	-	-	-
EBT, Excl. Unusual Items	-13.54M	-59.44M	-149M	-168M	-236M
Gain (Loss) On Sale Of Investments	-	-	-8K	-34K	-23K
Other Unusual Items	-1.32M	-	-	-	-
EBT, Incl. Unusual Items	-14.86M	-59.44M	-149M	-168M	-236M
Earnings From Continuing Operations	-14.86M	-59.44M	-149M	-168M	-236M
Net Income to Company	-14.86M	-59.44M	-149M	-168M	-236M
Net Income - (IS)	-14.86M	-59.44M	-149M	-168M	-236M
Net Income to Common Incl Extra Items	-14.86M	-59.44M	-149M	-168M	-236M
Net Income to Common Excl. Extra Items	-14.86M	-59.44M	-149M	-168M	-236M
Per Share Items
Net EPS - Basic	-6.08	-4.13	-2.93	-3.23	-3.95
Basic EPS - Continuing Operations	-6.08	-4.13	-2.93	-3.23	-3.95
Basic Weighted Average Shares Outstanding	2.44M	14.4M	50.9M	51.98M	59.68M
Net EPS - Diluted	-6.08	-4.13	-2.93	-3.23	-3.95
Diluted EPS - Continuing Operations	-6.08	-4.13	-2.93	-3.23	-3.95
Diluted Weighted Average Shares Outstanding	2.44M	14.4M	50.9M	51.98M	59.68M
Normalized Basic EPS	-3.46	-2.58	-1.83	-2.02	-2.47
Normalized Diluted EPS	-3.46	-2.58	-1.83	-2.02	-2.47
Supplemental Items
EBITDA	-13.56M	-57.95M	-149M	-169M	-240M
EBITA	-13.83M	-58.65M	-150M	-171M	-242M
EBIT	-13.83M	-58.65M	-150M	-171M	-242M
EBITDAR	-12.86M	-57.15M	-147M	-162M	-233M
Normalized Net Income	-8.46M	-37.15M	-93.3M	-105M	-147M
Supplemental Operating Expense Items
General and Administrative Expenses	2.79M	13.45M	28.72M	28.2M	31.4M
Research And Development Expense From Footnotes	11.04M	45.2M	121M	143M	211M
Net Rental Expense, Total	700K	800K	2.1M	7.39M	7.54M
Stock-Based Comp., R&D Exp. (Total)	13K	2.7M	7.33M	8.22M	11.58M
Stock-Based Comp., G&A Exp. (Total)	13K	3.89M	10.21M	6.96M	8.39M
Total Stock-Based Compensation	26K	6.59M	17.54M	15.18M	19.97M

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	14.63M	301M	201M	172M	122M
Short Term Investments	-	44.46M	176M	83.86M	1.47M
Total Cash And Short Term Investments	14.63M	345M	377M	256M	123M
Prepaid Expenses	127K	3.77M	5.44M	9.58M	6.28M
Restricted Cash	-	-	383K	-	-
Total Current Assets	14.76M	349M	382M	266M	129M
Gross Property Plant And Equipment	1.78M	2.94M	42.94M	42.04M	38.68M
Accumulated Depreciation	-295K	-995K	-1.98M	-3.63M	-5.29M
Net Property Plant And Equipment	1.49M	1.95M	40.96M	38.41M	33.39M
Other Long-Term Assets, Total	191K	2.3M	2.31M	2.32M	2.32M
Total Assets	16.44M	353M	426M	306M	165M
Liabilities
Accounts Payable, Total	1.26M	3.44M	4.03M	5.26M	22.94M
Accrued Expenses, Total	1.08M	7.48M	20.74M	18.22M	23.44M
Current Portion of Leases	-	-	3.89M	4.61M	4.72M
Other Current Liabilities	18K	52K	62K	1K	-
Total Current Liabilities	2.36M	10.97M	28.72M	28.09M	51.1M
Long-Term Debt	-	-	-	-	-
Long-Term Leases	-	-	28.74M	25.87M	22.7M
Other Non Current Liabilities	42K	-	-	-	-
Total Liabilities	2.4M	10.97M	57.47M	53.96M	73.79M
Preferred Stock Convertible	27.43M	-	-	-	-
Total Preferred Equity	27.43M	-	-	-	-
Common Stock, Total	1K	5K	6K	6K	6K
Additional Paid In Capital	6.35M	422M	597M	650M	724M
Retained Earnings	-19.75M	-79.18M	-228M	-397M	-633M
Comprehensive Income and Other	-	-27K	-269K	-571K	-
Total Common Equity	-13.39M	342M	368M	252M	91.29M
Total Equity	14.04M	342M	368M	252M	91.29M
Total Liabilities And Equity	16.44M	353M	426M	306M	165M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	2.59M	51.46M	51.6M	56.34M	81.96M
ECS Total Common Shares Outstanding	2.59M	45.45M	51.53M	55.63M	61.47M
Book Value / Share	-5.18	7.53	7.15	4.54	1.49
Tangible Book Value	-13.39M	342M	368M	252M	91.29M
Tangible Book Value Per Share	-5.18	7.53	7.15	4.54	1.49
Total Debt	0	0	32.64M	30.48M	27.42M
Net Debt	-14.63M	-345M	-344M	-226M	-95.68M
Debt Equivalent Oper. Leases	5.6M	6.4M	16.8M	59.13M	60.36M
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	1.77M	2.82M	5.2M	8.67M	9.64M
Full Time Employees	-	47	93	119	141

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	-14.86M	-59.44M	-149M	-168M	-236M
Depreciation & Amortization - CF	271K	700K	1.09M	1.68M	1.67M
Depreciation & Amortization, Total	271K	700K	1.09M	1.68M	1.67M
Amortization of Deferred Charges, Total - (CF)	-	64K	-	-	-
(Gain) Loss From Sale Of Asset	-	-	-	-	118K
(Gain) Loss on Sale of Investments - (CF)	-	12K	2.59M	1.31M	-1.08M
Stock-Based Compensation (CF)	26K	6.59M	17.54M	15.18M	19.97M
Other Operating Activities, Total	1.32M	450K	-746K	1.66M	788K
Change In Accounts Payable	1.69M	8.57M	13.7M	-1.24M	22.97M
Change in Other Net Operating Assets	-284K	-3.46M	-4.45M	-4.14M	3.34M
Cash from Operations	-11.83M	-46.51M	-120M	-154M	-188M
Capital Expenditure	-1.65M	-1.16M	-3.62M	-3.07M	-729K
Investment in Marketable and Equity Securities, Total	-	-44.5M	-134M	90.27M	84.04M
Cash from Investing	-1.65M	-45.66M	-138M	87.2M	83.31M
Long-Term Debt Issued, Total	-	9.94M	-	-	-
Total Debt Issued	-	9.94M	-	-	-
Long-Term Debt Repaid, Total	-	-10M	-	-	-
Total Debt Repaid	-	-10M	-	-	-
Issuance of Common Stock	-	246M	158M	37.39M	54.32M
Issuance of Preferred Stock	19.99M	135M	-	-	-
Other Financing Activities, Total	-	-450K	-	-	-
Cash from Financing	19.99M	381M	158M	37.39M	54.32M
Net Change in Cash	6.51M	289M	-99.63M	-29.05M	-50.52M
Supplemental Items
Cash Interest Paid	-	328K	-	-	-
Levered Free Cash Flow	-8.44M	-25.74M	-66.94M	-98.17M	-104M
Unlevered Free Cash Flow	-8.44M	-25.56M	-66.94M	-98.17M	-104M
Change In Net Working Capital	-1.55M	-4.96M	-11.82M	5.11M	-26.2M
Net Debt Issued / Repaid	-	-64K	-	-	-

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	-69.96	-19.83	-24.07	-29.19	-64.21
Return on Total Capital	-80.04	-20.57	-25.23	-31.26	-75.38
Return On Equity %	-163.12	-33.35	-42.02	-54.18	-137.31
Return on Common Equity	162.64	-36.13	-42.02	-54.18	-137.31
Short Term Liquidity
Current Ratio	6.26	31.83	13.31	9.46	2.53
Quick Ratio	6.21	31.49	13.11	9.11	2.41
Operating Cash Flow to Current Liabilities	-5.02	-4.24	-4.16	-5.47	-3.68
Long Term Solvency
Total Debt/Equity	-	-	8.86	12.08	30.03
Total Debt / Total Capital	-	-	8.14	10.78	23.09
LT Debt/Equity	-	-	7.81	10.25	24.86
Long-Term Debt / Total Capital	-	-	7.17	9.15	19.12
Total Liabilities / Total Assets	14.6	3.1	13.5	17.62	44.7
EBIT / Interest Expense	-	-148.1	-	-	-
EBITDA / Interest Expense	-	-146.33	-	-	-
(EBITDA - Capex) / Interest Expense	-	-149.26	-	-	-
Total Debt / EBITDA	-	-	-0.22	-0.19	-0.12
Net Debt / EBITDA	1.08	5.96	2.34	1.39	0.41
Total Debt / (EBITDA - Capex)	-	-	-0.22	-0.18	-0.12
Net Debt / (EBITDA - Capex)	0.96	5.84	2.29	1.37	0.41
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	184.11	327.5	157.02	13.66	42.07
EBITA, 1 Yr. Growth %	188.34	324.18	155.81	13.96	41.65
EBIT, 1 Yr. Growth %	188.34	324.18	155.81	13.96	41.65
Earnings From Cont. Operations, 1 Yr. Growth %	208.85	300.01	151.18	12.6	40.36
Net Income, 1 Yr. Growth %	208.85	300.01	151.18	12.6	40.36
Normalized Net Income, 1 Yr. Growth %	182.59	339.1	151.16	12.58	40.37
Diluted EPS Before Extra, 1 Yr. Growth %	-40.06	-32.12	-28.95	10.26	22.23
Net Property, Plant and Equip., 1 Yr. Growth %	1.25K	30.96	2K	-6.22	-13.07
Total Assets, 1 Yr. Growth %	98.79	2.05K	20.47	-28.04	-46.11
Tangible Book Value, 1 Yr. Growth %	174.5	-2.66K	7.54	-31.46	-63.83
Common Equity, 1 Yr. Growth %	174.5	-2.66K	7.54	-31.46	-63.83
Cash From Operations, 1 Yr. Growth %	184.2	293	157.08	28.51	22.46
Capital Expenditures, 1 Yr. Growth %	1.13K	-29.51	211.63	-15.23	-76.23
Levered Free Cash Flow, 1 Yr. Growth %	-	205.13	160.01	46.66	6.17
Unlevered Free Cash Flow, 1 Yr. Growth %	-	202.96	161.87	46.66	6.17
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	-	248.51	231.48	70.92	27.07
EBITA, 2 Yr. CAGR %	-	249.73	229.41	70.74	27.05
EBIT, 2 Yr. CAGR %	-	249.73	229.41	70.74	27.05
Earnings From Cont. Operations, 2 Yr. CAGR %	-	251.49	216.97	68.17	25.71
Net Income, 2 Yr. CAGR %	-	251.49	216.97	68.17	25.71
Normalized Net Income, 2 Yr. CAGR %	-	252.26	232.09	68.16	25.71
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-36.22	-30.56	-11.49	16.09
Net Property, Plant and Equip., 2 Yr. CAGR %	-	320.61	425.01	344.29	-9.71
Total Assets, 2 Yr. CAGR %	-	553.72	408.9	-6.89	-37.72
Tangible Book Value, 2 Yr. CAGR %	-	737.68	424.33	-14.14	-50.21
Common Equity, 2 Yr. CAGR %	-	737.68	424.33	-14.14	-50.21
Cash From Operations, 2 Yr. CAGR %	-	234.2	217.86	81.76	25.45
Capital Expenditures, 2 Yr. CAGR %	-	194.35	48.21	62.53	-55.11
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	181.67	95.27	24.78
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	181.67	95.97	24.78
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-	-	214.87	132.01	60.7
EBITA, 3 Yr. CAGR %	-	-	215.11	131.24	60.43
EBIT, 3 Yr. CAGR %	-	-	215.11	131.24	60.43
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	214.24	124.49	58.34
Net Income, 3 Yr. CAGR %	-	-	214.24	124.49	58.34
Normalized Net Income, 3 Yr. CAGR %	-	-	214.7	131.56	58.33
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-33.89	-18.99	-1.44
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	619.43	195.68	157.93
Total Assets, 3 Yr. CAGR %	-	-	272.01	165.13	-22.4
Tangible Book Value, 3 Yr. CAGR %	-	-	322.59	166.1	-35.64
Common Equity, 3 Yr. CAGR %	-	-	322.59	166.1	-35.64
Cash From Operations, 3 Yr. CAGR %	-	-	206.22	135.03	59.34
Capital Expenditures, 3 Yr. CAGR %	-	-	200	23.03	-14.37
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	-	126.6	59.38
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	-	126.6	59.76
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-	-	-	-	119.03
EBITA, 5 Yr. CAGR %	-	-	-	-	119.11
EBIT, 5 Yr. CAGR %	-	-	-	-	119.11
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	-	117.83
Net Income, 5 Yr. CAGR %	-	-	-	-	117.83
Normalized Net Income, 5 Yr. CAGR %	-	-	-	-	118.01
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-	-17.19
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	-	-	213.65
Total Assets, 5 Yr. CAGR %	-	-	-	-	82
Tangible Book Value, 5 Yr. CAGR %	-	-	-	-	79.65
Common Equity, 5 Yr. CAGR %	-	-	-	-	79.65
Cash From Operations, 5 Yr. CAGR %	-	-	-	-	114.29
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-	40.32